Sökning: onr:"swepub:oai:DiVA.org:liu-146043" >
Lipoprotein apheres...
Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
-
- Lappegård, Knut Tore (författare)
- Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
-
- Kjellmo, Christian Abendstein (författare)
- Division of Internal Medicine, Nordland Hospital, Bodø, Norway
-
- Ljunggren, Stefan A (författare)
- Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin
-
visa fler...
-
- Cederbrant, Karin (författare)
- Swedish Toxicology Sciences Research Center, Södertälje, Sweden
-
- Marcusson-Ståhl, Maritha (författare)
- Swedish Toxicology Sciences Research Center, Södertälje, Sweden
-
- Mathisen, Monica (författare)
- Research Laboratory, Nordland Hospital, Bodø, Norway
-
- Karlsson, Helen (författare)
- Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin
-
- Hovland, Anders (författare)
- Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2018
- 2018
- Engelska.
-
Ingår i: Transfusion and apheresis science. - : Elsevier BV. - 1473-0502 .- 1878-1683. ; 57:1, s. 91-96
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
http://liu.diva-port...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH). We explored changes in lipoprotein subclasses and high-density lipoprotein (HDL) function when changing treatment from lipoprotein apheresis to PCSK9 inhibition. We measured the levels of low-density lipoprotein (LDL) and HDL particle subclasses, serum amyloid A1 (SAA1), paraoxonase-1 (PON1) activity and cholesterol efflux capacity (CEC) in three heterozygous FH patients. Concentrations of all LDL particle subclasses were reduced during apheresis (large 68.0 ± 17.5 to 16.3 ± 2.1 mg/dL, (p = 0.03), intermediate 38.3 ± 0.6 to 5.0 ± 3.5 mg/dL (p = 0.004) and small 5.0 ± 2.6 to 0.2 ± 0.1 mg/dL (p = 0.08)). There were non-significant reductions in the LDL subclasses during evolocumab treatment. There were non-significant reductions in subclasses of HDL particles during apheresis, and no changes during evolocumab treatment. CEC was unchanged throughout the study, while the SAA1/PON1 ratio was unchanged during apheresis but decreased during evolocumab treatment. In conclusion, there were significant reductions in large and intermediate size LDL particles during apheresis, and a non-significant reduction in small LDL particles. There were only non-significant reductions in the LDL subclasses during evolocumab treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Cholesterol
- LDL&HIPHEN
- Lipoprotein apheresis
- Lipoprotein particles
- PCSK9-inhibition
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas